FASL antibody

Catalog No. ABIN1176980

Product Details anti-FASL Antibody

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Reactivity: Mouse, Rat

Host: Armenian Hamster

Clonality: Monoclonal

Conjugate: This FASL antibody is un-conjugated

Application: Flow Cytometry (FACS), Blocking Reagent (BR)

Brand: BD Pharmingen™

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Sterility: 0.2 μm filtered

Endotoxin Level: Endotoxin level is ≤ 0.01 EU/μg (≤ 0.001 ng/μg) of protein as determined by the LAL assay.

Immunogen: Mouse FasL transfected cells

Clone: MFL4

Isotype: IgG3 kappa

Application Details

Application Notes: We have found that enriched splenic T cells are induced to express Fas Ligand by 6 - 8-hour culture with plate-bound anti-alphabeta TCR mAb R73 (Cat. No. 554910) and anti-rat CD28 mAb JJ316 (Cat. No. 554992). Because Fas Ligand is expressed at low density on activated cells, we recommend the use of a biotinylated second-step antibody, such as polyclonal goat anti-hamster IgG, with a bright third-step reagent, such as Streptavidin-PE (Cat. No. 554061). Other reported applications include blocking of the cytotoxic activities of mFasL-transfected L5178Y T lymphoma, rFasL-transfected COS cells, and rFasL-transfected L5178Y cells.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: Aqueous buffered solution containing no preservative, 0.2μm filtered. Endotoxin level is ≤0.01 ng/μg of protein.

Preservative: Azide free

Storage: 4 °C

Storage Comment: This preparation contains no preservatives, thus it should be handled under aseptic conditions. Store undiluted at 4°C.

References for anti-FASL antibody (ABIN1176980)

Trinité, Voisine, Yagita, Josien: "A subset of cytolytic dendritic cells in rat." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 165, Issue 8, pp. 4202-8, (2000) (PubMed).

Moalem, Monsonego, Shani, Cohen, Schwartz: "Differential T cell response in central and peripheral nerve injury: connection with immune privilege." in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 13, Issue 10, pp. 1207-17, (1999) (PubMed).

Müschen, Warskulat, Douillard, Gilbert, Häussinger: "Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells." in: Hepatology (Baltimore, Md.), Vol. 27, Issue 1, pp. 200-8, (1998) (PubMed).

White, McCombe, Pender: "The roles of Fas, Fas ligand and Bcl-2 in T cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis." in: Journal of neuroimmunology, Vol. 82, Issue 1, pp. 47-55, (1998) (PubMed).

Kayagaki, Yamaguchi, Nagao, Matsuo, Maeda, Okumura, Yagita: "Polymorphism of murine Fas ligand that affects the biological activity." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, Issue 8, pp. 3914-9, (1997) (PubMed).

Griffith, Brunner, Fletcher, Green, Ferguson: "Fas ligand-induced apoptosis as a mechanism of immune privilege." in: Science (New York, N.Y.), Vol. 270, Issue 5239, pp. 1189-92, (1996) (PubMed).

Kayagaki, Kawasaki, Ebata, Ohmoto, Ikeda, Inoue, Yoshino, Okumura, Yagita: "Metalloproteinase-mediated release of human Fas ligand." in: The Journal of experimental medicine, Vol. 182, Issue 6, pp. 1777-83, (1996) (PubMed).

Suda, Okazaki, Naito, Yokota, Arai, Ozaki, Nakao, Nagata: "Expression of the Fas ligand in cells of T cell lineage." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 154, Issue 8, pp. 3806-13, (1995) (PubMed).

Brunner, Mogil, LaFace, Yoo, Mahboubi, Echeverri, Martin, Force, Lynch, Ware: "Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas." in: Nature, Vol. 373, Issue 6513, pp. 441-4, (1995) (PubMed).

Vignaux, Vivier, Malissen, Depraetere, Nagata, Golstein: "TCR/CD3 coupling to Fas-based cytotoxicity." in: The Journal of experimental medicine, Vol. 181, Issue 2, pp. 781-6, (1995) (PubMed).

Smith, Farrah, Goodwin: "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death." in: Cell, Vol. 76, Issue 6, pp. 959-62, (1994) (PubMed).

Target Details for FASL

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Alternative Name: CD178 (FASL Products)

Background: The MFL4 antibody, generated against mouse CD178 (Fas Ligand, CD95 Ligand), cross-reacts with the rat Fas Ligand antigen. MFL4 mAb detects rat Fas Ligand expressed by transfected cells, but not the parental cell line. In addition, the epitope detected by MFL4 can be induced on activated rat splenic T lymphocytes. The MFL4 mAb has been reported to inhibit killing of mouse lymphoma line A20.2J by rat FasL-transfected cells. The tissue distribution of mouse Fas Ligand has been well characterized. It is expressed at the mRNA and protein levels in a variety of tissues and cell types, including spleen, bone marrow, testis, uterus, eye, and activated lymphocytes. The expression of Fas Ligand in the rat has been detected in liver Kupffer cells, T cells in the central nervous system, spleen, and corpus luteum. MFL4 antibody reacts with the mouse Fas Ligand protein in a pattern similar to that of MFL3 antibody (Cat. No. 555291). Fas Ligand is a type-II transmembrane protein, a member of the TNF/NGF superfamily and a ligand for Fas (CD95). Fas Ligand and its counter-receptor CD95 are believed to participate in T-cell development, the regulation of immune responses, and cell-mediated cytotoxic mechanisms. It has been reported that human Fas Ligand is released from the surface of activated lymphocytes by metalloproteinase.
Synonyms: Fas Ligand, CD95 Ligand

Pathways: Apoptosis, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity